Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Schizophrenia

Free Subscription Articles published in Psychiatry Res Retrieve available abstracts of 362 articles: HTML format

Single Articles

June 2024
1. ROTELLA F, Falone A, Cassioli E, Mannucci E, et al
   The effect of differences in trial design on estimates of efficacy of olanzapine in randomized studies.
   Psychiatry Res. 2024;336:115895.
   PubMed     Abstract available
   
   
   May 2024
2. WU Y, Zhang CY, Zhang Y, Chen R, et al
   Genomic landscape and functional characterization of structural variations in schizophrenia and bipolar disorder.
   Psychiatry Res. 2024;337:115929.
   PubMed     Abstract available
   
   
   April 2024
3. GUO H, Zhong S, Lam ST, Wang N, et al
   Trends in violent offending among people with schizophrenia: A 10-year ecological study.
   Psychiatry Res. 2024;337:115935.
   PubMed     Abstract available
   
   
   
4. BRADLEY ER, Portanova J, Woolley JD, Buck B, et al
   Quantifying abnormal emotion processing: A novel computational assessment method and application in schizophrenia.
   Psychiatry Res. 2024;336:115893.
   PubMed     Abstract available
   
   
   
5. SMITH LC, Mateos AC, Due AS, Bergstrom J, et al
   Immersive virtual reality in the treatment of auditory hallucinations: A PRISMA scoping review.
   Psychiatry Res. 2024;334:115834.
   PubMed     Abstract available
   
   
   March 2024
6. SPINAZZOLA E, Quattrone D, Quattrone A, Murray RM, et al
   The increased incidence of psychosis during the COVID-19 pandemic in South London: The role of heavy cannabis use.
   Psychiatry Res. 2024;336:115869.
   PubMed    
   
   
   
7. HAMZEHPOUR L, Bohn T, Dutsch V, Jaspers L, et al
   From brain to body: exploring the connection between altered reward processing and physical fitness in schizophrenia.
   Psychiatry Res. 2024;335:115877.
   PubMed     Abstract available
   
   
   
8. GALLEGO JA, McNamara RK, Blanco EA, Castaneda S, et al
   Evidence for cytokine dysregulation in schizophrenia spectrum disorders: A comparison of cerebrospinal fluid and blood samples.
   Psychiatry Res. 2024;335:115871.
   PubMed     Abstract available
   
   
   
9. SEFIK E, Guest RM, Aberizk K, Espana R, et al
   Psychosis spectrum symptoms among individuals with schizophrenia-associated copy number variants and evidence of cerebellar correlates of symptom severity.
   Psychiatry Res. 2024;335:115867.
   PubMed     Abstract available
   
   
   
10. SETHI S, Wakeham D, Ketter T, Hooshmand F, et al
    Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial.
    Psychiatry Res. 2024;335:115866.
    PubMed     Abstract available
    
    
    
11. YANG H, Zhu D, Liu Y, Xu Z, et al
    Employing graph attention networks to decode psycho-metabolic interactions in Schizophrenia.
    Psychiatry Res. 2024;335:115841.
    PubMed     Abstract available
    
    
    
12. KISHI T, Citrome L, Sakuma K, Iwata N, et al
    A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.
    Psychiatry Res. 2024;333:115761.
    PubMed     Abstract available
    
    
    February 2024
13. GORORA ME, Dalkner N, Moore RC, Depp CA, et al
    A meta-cognitive Wisconsin Card Sorting Test in people with schizophrenia and bipolar disorder: Self-assessment of sorting performance.
    Psychiatry Res. 2024;334:115831.
    PubMed     Abstract available
    
    
    
14. QIN K, Yu Y, Cai H, Li J, et al
    Effectiveness of mindfulness-based intervention in schizophrenia: A meta-analysis of randomized controlled trials.
    Psychiatry Res. 2024;334:115808.
    PubMed     Abstract available
    
    
    
15. KIKUCHI Y, Komatsu H, Otsuka Y, Ito F, et al
    Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia.
    Psychiatry Res. 2024;334:115810.
    PubMed     Abstract available
    
    
    
16. GOODING DC, Mohrbacher DA, Umucu E, Van Hulle CA, et al
    Ethnoracialized group differences in attitudes and knowledge about schizophrenia and willingness to engage in biomarker research: The UBIGR Study.
    Psychiatry Res. 2024;334:115776.
    PubMed     Abstract available
    
    
    
17. HYATT AS, Mulvaney-Day N, Chow CM, Cook BL, et al
    Association between electronic nicotine product use and subsequent first episode psychosis.
    Psychiatry Res. 2024;334:115785.
    PubMed     Abstract available
    
    
    
18. KWAK PP, Ibarra C, Hernandez A, Carrasco J, et al
    Differences in metabolic biomarkers in people with schizophrenia who are of Mexican descent compared to non-Hispanic whites.
    Psychiatry Res. 2024;334:115788.
    PubMed     Abstract available
    
    
    
19. QUIRINO AHA, da Rocha MEC, Andrade AGM, E Souza FGM, et al
    The demonstrated association: Cannabis use and onset of psychosis in the study by Medeiros et al., refuting the reverse notion.
    Psychiatry Res. 2024;334:115771.
    PubMed    
    
    
    January 2024
20. HE R, Palominos C, Zhang H, Alonso-Sanchez MF, et al
    Navigating the semantic space: Unraveling the structure of meaning in psychosis using different computational language models.
    Psychiatry Res. 2024;333:115752.
    PubMed     Abstract available
    
    
    
21. KOS C, Bais L, Klaasen N, Opmeer E, et al
    Effects of right prefrontal theta-burst transcranial magnetic stimulation or transcranial direct current stimulation on apathy in patients with schizophrenia: A multicenter RCT.
    Psychiatry Res. 2024;333:115743.
    PubMed     Abstract available
    
    
    
22. YI S, Wang Q, Wang W, Hong C, et al
    Efficacy of repetitive transcranial magnetic stimulation (rTMS) on negative symptoms and cognitive functioning in schizophrenia: An umbrella review of systematic reviews and meta-analyses.
    Psychiatry Res. 2024;333:115728.
    PubMed     Abstract available
    
    
    
23. TOUMAIAN M, Covanis P, Mantas A, Karantinos T, et al
    Multisensory integration deficits in Schizophrenia and Autism evidenced in behaviour but not event related potentials.
    Psychiatry Res. 2024;332:115727.
    PubMed     Abstract available
    
    
    
24. PROHENS L, Rodriguez N, Segura AG, Martinez-Pinteno A, et al
    Gene expression imputation provides clinical and biological insights into treatment-resistant schizophrenia polygenic risk.
    Psychiatry Res. 2024;332:115722.
    PubMed     Abstract available
    
    
    
25. JEROME L, Matanov A, Bird V, Priebe S, et al
    Comparison of subjective quality of life domains in schizophrenia, mood, and anxiety disorders; an individual patient data meta-analysis.
    Psychiatry Res. 2024;332:115707.
    PubMed     Abstract available
    
    
    
26. CHU RST, Chong RCH, Chang DHH, Shan Leung AL, et al
    The risk of stroke and post-stroke mortality in people with schizophrenia: A systematic review and meta-analysis study.
    Psychiatry Res. 2024;332:115713.
    PubMed     Abstract available
    
    
    
27. SETIEN-SUERO E, Ayesa-Arriola R, Pena J, Ojeda N, et al
    Premorbid adjustment as predictor of long-term functionality: Findings from a 10-year follow-up study in the PAFIP-cohort.
    Psychiatry Res. 2024;331:115674.
    PubMed     Abstract available
    
    
    
28. MASTELLARI T, Saint-Dizier C, Fovet T, Geoffroy PA, et al
    Exploring seasonality in catatonia diagnosis: Evidence from a large-scale population study.
    Psychiatry Res. 2024;331:115652.
    PubMed     Abstract available
    
    
    December 2023
29. WANG Y, Zhang X
    The role of immune inflammation in electroconvulsive therapy for schizophrenia: Treatment mechanism, and relationship with clinical efficacy: Immune-inflammation in ECT for schizophrenia.
    Psychiatry Res. 2023;332:115708.
    PubMed     Abstract available
    
    
    
30. VGONTZAS AN, Paschalidou A, Simos PG, Anastasaki M, et al
    Impact of long-acting injectable antipsychotics vs. oral medication on relapses of patients with psychosis and bipolar disorder.
    Psychiatry Res. 2023;332:115676.
    PubMed     Abstract available
    
    
    
31. TORREY EF
    Did the human genome project affect research on Schizophrenia?
    Psychiatry Res. 2023;333:115691.
    PubMed     Abstract available
    
    
    
32. KIM WS, Shen J, Tsogt U, Odkhuu S, et al
    Altered thalamic volumes and functional connectivity in the recovered patients with psychosis.
    Psychiatry Res. 2023;331:115688.
    PubMed     Abstract available
    
    
    
33. ZHOU D, Xie H, Chen L, Zhu Z, et al
    The cognitive improvement in patients with schizophrenia following low-intensity repetitive transcranial magnetic stimulation could last for 6 months: A randomized controlled trial.
    Psychiatry Res. 2023;332:115672.
    PubMed     Abstract available
    
    
    
34. CHEN Y, Zhang L, Sun Y, Wang W, et al
    Prevalence of constipation in patients with schizophrenia: A systematic review and meta-analysis.
    Psychiatry Res. 2023;331:115659.
    PubMed    
    
    
    
35. DE MEDEIROS MW, Andrade JC, Haddad NM, Mendonca M, et al
    Cannabis use influences disorganized symptoms severity but not transition in a cohort of non-help-seeking individuals at-risk for psychosis from Sao Paulo, Brazil.
    Psychiatry Res. 2023;331:115665.
    PubMed     Abstract available
    
    
    
36. DEAN B, Duce J, Li QX, Masters CL, et al
    Lower levels of soluble beta-amyloid precursor protein, but not beta-amyloid, in the frontal cortex in schizophrenia.
    Psychiatry Res. 2023;331:115656.
    PubMed     Abstract available
    
    
    
37. FENG XZ, Li Z, Li ZY, Wang K, et al
    Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis.
    Psychiatry Res. 2023;332:115637.
    PubMed     Abstract available
    
    
    
38. VINOGRADOV S
    Harnessing neuroplasticity.
    Psychiatry Res. 2023;330:115607.
    PubMed     Abstract available
    
    
    
39. STAFFORD E, Jakob S, Gur RE, Corcoran CM, et al
    Securing direct stakeholder feedback to inform clinical research in serious mental illness: Results of a patient and family perspectives survey.
    Psychiatry Res. 2023;330:115574.
    PubMed     Abstract available
    
    
    November 2023
40. GROENING JM, Denton E, Parvaiz R, Brunet DL, et al
    A systematic evidence map of the association between cannabis use and psychosis-related outcomes across the psychosis continuum: An umbrella review of systematic reviews and meta-analyses.
    Psychiatry Res. 2023;331:115626.
    PubMed     Abstract available
    
    
    
41. LAMANNA-RAMA N, Romero-Miguel D, Casquero-Veiga M, MacDowell KS, et al
    THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation.
    Psychiatry Res. 2023;331:115643.
    PubMed     Abstract available
    
    
    
42. WEI Z, Wang Y, Hu L, Wang Y, et al
    Incidence, prevalence, and mortality of schizophrenia from 2016 to 2020 in Shandong, China.
    Psychiatry Res. 2023;331:115612.
    PubMed     Abstract available
    
    
    
43. LEE J, Xue X, Au E, McIntyre WB, et al
    Central insulin dysregulation in antipsychotic-naive first-episode psychosis: In silico exploration of gene expression signatures.
    Psychiatry Res. 2023;331:115636.
    PubMed     Abstract available
    
    
    
44. CUESTA MJ, Gil-Berrozpe GJ, Sanchez-Torres AM, Moreno-Izco L, et al
    20-Year trajectories of six psychopathological dimensions in patients with first-episode psychosis: Could they be predicted?
    Psychiatry Res. 2023;331:115614.
    PubMed     Abstract available
    
    
    
45. HU Q, Jiao X, Zhou J, Tang Y, et al
    Low-frequency repetitive transcranial magnetic stimulation over the right orbitofrontal cortex for patients with first-episode schizophrenia: A randomized, double-blind, sham-controlled trial.
    Psychiatry Res. 2023;330:115600.
    PubMed     Abstract available
    
    
    
46. BOGE K, Hallford DJ, Pillny M
    Mindfulness, psychological flexibility and their relationship with psychopathology in persons with schizophrenia-spectrum-disorders and healthy controls - A multicenter cross-sectional study.
    Psychiatry Res. 2023;330:115591.
    PubMed     Abstract available
    
    
    
47. DAZZAN P
    Disentangling psychosis: The challenges of informing precision medicine for what is not a single disorder.
    Psychiatry Res. 2023;330:115596.
    PubMed     Abstract available
    
    
    
48. BERNARDIN F, Gauld C, Martin VP, Laprevote V, et al
    The 68 symptoms of the clinical high risk for psychosis: Low similarity among fourteen screening questionnaires.
    Psychiatry Res. 2023;330:115592.
    PubMed     Abstract available
    
    
    
49. CORNBLATT BA, McFarlane WR, Carrion RE
    Authors' reply to comments on: Recreational cannabis use over time in individuals at clinical high risk for psychosis: Lack of associations with symptom, neurocognitive, functioning, and treatment patterns.
    Psychiatry Res. 2023;330:115594.
    PubMed    
    
    
    
50. KIRSHENBAUM AP, Sofis MJ, Slade M
    Response to recreational cannabis use over time in individuals at clinical high risk for psychosis: lack of associations with symptom, neurocognitive, functioning, and treatment patterns by Carrion et al., 2023.
    Psychiatry Res. 2023;330:115589.
    PubMed    
    
    
    
51. PARK S
    Schizophrenia in the mind, the brain and the body.
    Psychiatry Res. 2023;329:115547.
    PubMed     Abstract available
    
    
    October 2023
52. BIRONG CHEN, Tan XW, Tor PC
    The impact of the number of previous illness episodes on early response to electroconvulsive therapy (ECT) in psychosis, mania, depression, psychotic depression, and catatonia: A naturalistic transdiagnostic analysis.
    Psychiatry Res. 2023;330:115580.
    PubMed     Abstract available
    
    
    
53. KIM HK, Goncalves VF, Husain MI, Muller DJ, et al
    Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia.
    Psychiatry Res. 2023;330:115563.
    PubMed     Abstract available
    
    
    
54. LIN CH, Huang CJ, Lin TC, Chan HY, et al
    Schizophrenia patients discharged on antipsychotic polypharmacy from a public psychiatric hospital in Taiwan, 2006-2021.
    Psychiatry Res. 2023;330:115575.
    PubMed     Abstract available
    
    
    
55. WANG P, Jiang Y, Hoptman MJ, Li Y, et al
    Structural-functional connectivity deficits of callosal-white matter-cortical circuits in schizophrenia.
    Psychiatry Res. 2023;330:115559.
    PubMed     Abstract available
    
    
    
56. VAN DER TUIN S, Booij SH, Muller MK, van den Berg D, et al
    The added value of daily diary data in 1- and 3-year prediction of psychopathology and psychotic experiences in individuals at risk for psychosis.
    Psychiatry Res. 2023;329:115546.
    PubMed     Abstract available
    
    
    
57. HASSAN L, Eisner E, Berry K, Emsley R, et al
    User engagement in a randomised controlled trial for a digital health intervention for early psychosis (Actissist 2.0 trial).
    Psychiatry Res. 2023;329:115536.
    PubMed     Abstract available
    
    
    
58. SCHLIEF M, Rich N, Rains LS, Baldwin H, et al
    Ethnic differences in receipt of psychological interventions in Early Intervention in Psychosis services in England - a cross-sectional study.
    Psychiatry Res. 2023;330:115529.
    PubMed     Abstract available
    
    
    
59. ZHANG T, Xu L, Wei Y, Tang X, et al
    Duration of untreated prodromal psychosis among individuals with clinical high risk for psychosis.
    Psychiatry Res. 2023;329:115522.
    PubMed     Abstract available
    
    
    September 2023
60. SAMPEDRO A, Pena J, Sanchez P, Ibarretxe-Bilbao N, et al
    Moderators of functional improvement after integrative cognitive remediation in schizophrenia: Toward a personalized treatment approach.
    Psychiatry Res. 2023;329:115495.
    PubMed     Abstract available
    
    
    
61. HUI CLM, Wong CCL, Chan EWT, Suen YN, et al
    COVID-19 exposure and psychosis: A comparison of clinical, functional, and cognitive profiles in remitted patients with psychosis.
    Psychiatry Res. 2023;328:115487.
    PubMed     Abstract available
    
    
    
62. CAMPRODON-BOADAS P, De la Serna E, Plana MT, Flamarique I, et al
    Delusional beliefs in adolescents with anorexia nervosa, obsessive-compulsive disorder, or first-episode psychosis: A comparative study.
    Psychiatry Res. 2023;328:115490.
    PubMed     Abstract available
    
    
    
63. BALDINI V, Stefano RD, Rindi LV, Ahmed AO, et al
    Association between adverse childhood experiences and suicidal behavior in schizophrenia spectrum disorders: A systematic review and meta-analysis.
    Psychiatry Res. 2023;329:115488.
    PubMed     Abstract available
    
    
    
64. GEBREEGZIABHERE Y, Habatmu K, Cella M, Alem A, et al
    Introducing an interview-based cognitive assessment tool for people with Schizophrenia in Ethiopia.
    Psychiatry Res. 2023;328:115474.
    PubMed     Abstract available
    
    
    
65. SANCHEZ-TORRES AM, Garcia de Jalon E, Gil-Berrozpe GJ, Peralta V, et al
    Cognitive intraindividual variability, cognitive impairment and psychosocial functioning in first-episode psychosis patients.
    Psychiatry Res. 2023;328:115473.
    PubMed     Abstract available
    
    
    
66. FORDHAM E, Gao CX, Filia K, O'Donoghue B, et al
    Social disadvantage in early psychosis and its effect on clinical presentation and service access, engagement and use.
    Psychiatry Res. 2023;328:115478.
    PubMed     Abstract available
    
    
    
67. MAURUS I, Roell L, Lembeck M, Papazova I, et al
    Exercise as an add-on treatment in individuals with schizophrenia: Results from a large multicenter randomized controlled trial.
    Psychiatry Res. 2023;328:115480.
    PubMed     Abstract available
    
    
    
68. INCHAUSTI L, Gorostiza I, Gonzalez Torres MA, Oraa R, et al
    The transition to Schizophrenia spectrum disorder from a first psychotic episode that did or did not appear to be induced by substance use.
    Psychiatry Res. 2023;328:115475.
    PubMed     Abstract available
    
    
    
69. FANG X, Gao C, Wu W, Hu X, et al
    The role of the gut microbiome in weight-gain in schizophrenia patients treated with atypical antipsychotics: Evidence based on altered composition and function in a cross-sectional study.
    Psychiatry Res. 2023;328:115463.
    PubMed     Abstract available
    
    
    
70. ZHANG J, Yang Y, Liu T, Shi Z, et al
    Functional connectivity in people at clinical and familial high risk for schizophrenia.
    Psychiatry Res. 2023;328:115464.
    PubMed     Abstract available
    
    
    
71. SMITH ECC, Au E, Pereira S, Sharma E, et al
    Clinical improvement in schizophrenia during antipsychotic treatment in relation to changes in glucose parameters: A systematic review.
    Psychiatry Res. 2023;328:115472.
    PubMed     Abstract available
    
    
    
72. LUCKHOFF HK, Asmal L, Smit R, Phahladira L, et al
    Sex, gender, and outcome in first-episode psychosis: The role of premorbid functioning.
    Psychiatry Res. 2023;328:115460.
    PubMed     Abstract available
    
    
    
73. SEGAL SP, Rimes L, Badran L
    Crime and victimization outcomes following civil rights limits to the use of compulsory treatment.
    Psychiatry Res. 2023;327:115377.
    PubMed     Abstract available
    
    
    
74. JOSHI YB, Gonzalez CE, Molina JL, MacDonald LR, et al
    Mismatch negativity predicts initial auditory-based targeted cognitive training performance in a heterogeneous population across psychiatric disorders.
    Psychiatry Res. 2023;327:115215.
    PubMed     Abstract available
    
    
    
75. XIE Y, Guan M, Wang Z, Ma Z, et al
    Alterations in brain connectivity patterns in schizophrenia patients with auditory verbal hallucinations during low frequency repetitive transcranial magnetic stimulation.
    Psychiatry Res. 2023;328:115457.
    PubMed     Abstract available
    
    
    August 2023
76. KUUSKMAE C, Philips MA, Kilk K, Haring L, et al
    Kynurenine pathway dynamics in patients with schizophrenia spectrum disorders across the disease trajectory.
    Psychiatry Res. 2023;328:115423.
    PubMed     Abstract available
    
    
    
77. CARRION RE, Auther AM, McLaughlin D, Adelsheim S, et al
    Recreational cannabis use over time in individuals at clinical high risk for psychosis: Lack of associations with symptom, neurocognitive, functioning, and treatment patterns.
    Psychiatry Res. 2023;328:115420.
    PubMed     Abstract available
    
    
    
78. ZHANG Y, Lu Z, Sun Y, Zhang X, et al
    Predictive role of pulvinar in social functional outcome of schizophrenia.
    Psychiatry Res. 2023;327:115419.
    PubMed     Abstract available
    
    
    
79. JOHANSSON M, Hjarthag F, Helldin L
    Exploring cross-sectional and longitudinal symptomatic remission and subjective quality of life in schizophrenia.
    Psychiatry Res. 2023;328:115421.
    PubMed     Abstract available
    
    
    
80. FEKIH-ROMDHANE F, Abassi B, Ghrissi F, Loch AA, et al
    Suicide risk among individuals at Ultra-High Risk (UHR) of psychosis in a developing North African country: A 12-month naturalistic prospective cohort study from the TRIP project.
    Psychiatry Res. 2023;327:115409.
    PubMed     Abstract available
    
    
    
81. ALEKSANDROWICZ A, Kowalski J, Stefaniak I, Elert K, et al
    Cognitive correlates of auditory hallucinations in schizophrenia spectrum disorders.
    Psychiatry Res. 2023;327:115372.
    PubMed     Abstract available
    
    
    
82. LIU X, Xu L, Gong J, Ye Q, et al
    The effect of high-dose accelerated continuous theta burst stimulation (cTBS) treatment on auditory verbal hallucinations (AVH): A pilot study.
    Psychiatry Res. 2023;326:115337.
    PubMed    
    
    
    
83. LOCH AA, Pinto MTC, Andrade JC, de Jesus LP, et al
    Plasma levels of neurotrophin 4/5, NGF and pro-BDNF influence transition to mental disorders in a sample of individuals at ultra-high risk for psychosis.
    Psychiatry Res. 2023;327:115402.
    PubMed     Abstract available
    
    
    July 2023
84. HEMAGER N, Gregersen M, Christiani CJ, Hjorthoj C, et al
    Development of social functioning in preadolescent children at familial high-risk of schizophrenia or bipolar disorder - a 4-year follow-up study from age 7 to 11.
    Psychiatry Res. 2023;327:115397.
    PubMed     Abstract available
    
    
    
85. DAI J, Zhang MZ, He QQ, Chen R, et al
    The emerging role of exosomes in Schizophrenia.
    Psychiatry Res. 2023;327:115394.
    PubMed     Abstract available
    
    
    
86. KONDRATYEV NV, Alfimova MV, Kaleda VG, Lezheiko TV, et al
    Assessing the impact of the de novo SLC6A1 mutation in schizophrenia through a comprehensive case study.
    Psychiatry Res. 2023;327:115399.
    PubMed    
    
    
    
87. ZHANG T, Wei Y, Cui H, Tang X, et al
    Associations between age and neurocognition in individuals at clinical high risk and first-episode psychosis.
    Psychiatry Res. 2023;327:115385.
    PubMed     Abstract available
    
    
    
88. WANG C, Tishler TA, Nuechterlein KH, Ellingson BM, et al
    Cortical thickness, gray-white matter contrast, and intracortical myelin in first-episode schizophrenia patients treated with long-acting paliperidone palmitate versus oral antipsychotics.
    Psychiatry Res. 2023;326:115364.
    PubMed     Abstract available
    
    
    June 2023
89. CHEN X, Tan W, Cheng Y, Huang D, et al
    Polygenic risk for schizophrenia and the language network: Putative compensatory reorganization in unaffected siblings.
    Psychiatry Res. 2023;326:115319.
    PubMed     Abstract available
    
    
    
90. PANARIELLO F, Zamparini M, Picchioni M, Nielssen OB, et al
    Exposure to violence in childhood and risk of violence in adult schizophrenia: Results from a multinational study.
    Psychiatry Res. 2023;326:115299.
    PubMed     Abstract available
    
    
    
91. CHU RYK, Wei Y, Osborn DP, Ng VWS, et al
    Breast cancer risks following antipsychotic use in women with bipolar disorder versus schizophrenia: A territory-wide nested case-control study spanning two decades.
    Psychiatry Res. 2023;326:115287.
    PubMed     Abstract available
    
    
    
92. OKADA H, Sawamura D, Kunita K, Ogasawara H, et al
    Prefrontal activation during simulated driving in people with schizophrenia: A functional near-infrared spectroscopy study.
    Psychiatry Res. 2023;326:115285.
    PubMed     Abstract available
    
    
    May 2023
93. VEDDUM L, Greve AN, Gregersen M, Andreassen AK, et al
    A study of the genetic architecture of social responsiveness in families with parental schizophrenia or bipolar disorder and population-based controls.
    Psychiatry Res. 2023;326:115280.
    PubMed     Abstract available
    
    
    
94. TATAR O, Abdel-Baki A, Dyachenko A, Bakouni H, et al
    Evaluating preferences for online psychological interventions to decrease cannabis use in young adults with psychosis: An observational study.
    Psychiatry Res. 2023;326:115276.
    PubMed     Abstract available
    
    
    
95. LEE JJ, Piras E, Tamburini S, Bu K, et al
    Gut and oral microbiome modulate molecular and clinical markers of schizophrenia-related symptoms: A transdiagnostic, multilevel pilot study.
    Psychiatry Res. 2023;326:115279.
    PubMed     Abstract available
    
    
    
96. SHADOWEN N, Meehan Z, Webb C, Fowles T, et al
    Early intervention in youth psychosis: Novel approaches to understanding change.
    Psychiatry Res. 2023;326:115269.
    PubMed     Abstract available
    
    
    
97. COHN J
    Elaboration of some points in "The association of gender dysphoria with psychosis".
    Psychiatry Res. 2023;325:115264.
    PubMed    
    
    
    
98. LI Q, Gong Y, Cui Y, Cheng C, et al
    Efficacy of transcutaneous electrical acupoint stimulation for patients with first-episode schizophrenia: An 8-week, preliminary, randomized controlled trial.
    Psychiatry Res. 2023;325:115255.
    PubMed     Abstract available
    
    
    
99. WOJTALIK JA, Brown WJ, Mesholam-Gately RI, Kotwani A, et al
    Predictors of treatment discontinuation during an 18-month multi-site randomized trial of Cognitive Enhancement Therapy for early course schizophrenia.
    Psychiatry Res. 2023;326:115254.
    PubMed     Abstract available
    
    
    
100. CIAMPELLI S, Voppel AE, de Boer JN, Koops S, et al
     Combining automatic speech recognition with semantic natural language processing in schizophrenia.
     Psychiatry Res. 2023;325:115252.
     PubMed     Abstract available
     
     
     
101. ZHANG H, Parola A, Zhou Y, Wang H, et al
     Linguistic markers of psychosis in Mandarin Chinese: Relations to theory of mind.
     Psychiatry Res. 2023;325:115253.
     PubMed     Abstract available
     
     
     
102. REICH N, Delavari F, Schneider M, Thillainathan N, et al
     Multivariate patterns of disrupted sleep longitudinally predict affective vulnerability to psychosis in 22q11.2 Deletion Syndrome.
     Psychiatry Res. 2023;325:115230.
     PubMed     Abstract available
     
     
     
103. SANCHEZ RUIZ JA, Coombes BJ, Pendegraft RS, Ozerdem A, et al
     Pharmacotherapy exposure as a marker of disease complexity in bipolar disorder: Associations with clinical & genetic risk factors.
     Psychiatry Res. 2023;323:115174.
     PubMed     Abstract available
     
     
     
104. BUCK B, Wingerson M, Chander A, Tauscher JS, et al
     A preliminary study examining terminology used by individuals with lived experience describing beliefs about being targeted or harmed by others.
     Psychiatry Res. 2023;323:115129.
     PubMed     Abstract available
     
     
     April 2023
105. FUNG VSC, Chan JCY, Wong SCY, Wong CSM, et al
     Investigation of momentary negative symptoms in patients with early psychosis in daily life: An experience sampling study.
     Psychiatry Res. 2023;325:115234.
     PubMed     Abstract available
     
     
     
106. TOLL A, Pechuan E, Berge D, Legido T, et al
     Factors associated with suicide attempts in first-episode psychosis during the first two years after onset.
     Psychiatry Res. 2023;325:115232.
     PubMed     Abstract available
     
     
     
107. BENUTO LT, Done M, Zepeda M, Fitzgerald J, et al
     A systematic review of persons of color participation in first episode psychosis coordinated specialty care randomized controlled trials in North America.
     Psychiatry Res. 2023;325:115221.
     PubMed     Abstract available
     
     
     
108. TROTTI RL, Parker DA, Sabatinelli D, Keshavan MS, et al
     Emotional scene processing in biotypes of psychosis.
     Psychiatry Res. 2023;324:115227.
     PubMed     Abstract available
     
     
     
109. LU Z, Zhang Y, Sun Y, Liao Y, et al
     The positive association between antipsychotic-induced weight gain and therapeutic response: New biotypes of schizophrenia.
     Psychiatry Res. 2023;324:115226.
     PubMed     Abstract available
     
     
     
110. O'CONNELL KS, Koch E, Lenk HC, Akkouh IA, et al
     Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia.
     Psychiatry Res. 2023;325:115217.
     PubMed     Abstract available
     
     
     
111. DE THURAH L, Kiekens G, Sips R, Teixeira A, et al
     Using Experience Sampling Methods to support clinical management of psychosis: The perspective of people with lived experience.
     Psychiatry Res. 2023;324:115207.
     PubMed     Abstract available
     
     
     
112. ELVEVAG B
     Reflections on measuring disordered thoughts as expressed via language.
     Psychiatry Res. 2023;322:115098.
     PubMed     Abstract available
     
     
     
113. TONYALI A, Karacetin G, Ocakoglu BK, Atay A, et al
     Development and validation of Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) for Internet Gaming Disorder (IGD) and factor analytic assessment.
     Psychiatry Res. 2023;324:115187.
     PubMed     Abstract available
     
     
     March 2023
114. FUSAR-POLI L, Prachason T, Erzin G, Pries LK, et al
     Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study.
     Psychiatry Res. 2023;323:115184.
     PubMed     Abstract available
     
     
     
115. GARRIDO-TORRES N, Alameda L, Suarez MLS, Rocha Gonzalez I, et al
     Corrigendum "Higher rates of first episode psychosis in immigrants admitted in inpatient unit at southwest Spain" [Psychiatry Res. 308 (2022) 114352].
     Psychiatry Res. 2023 Mar 27:115146. doi: 10.1016/j.psychres.2023.115146.
     PubMed    
     
     
     
116. XU H, Zhou Y, Wang J, Liang Z, et al
     Effect of HD-tDCS on white matter integrity and associated cognitive function in chronic schizophrenia: A double-blind, sham-controlled randomized trial.
     Psychiatry Res. 2023;324:115183.
     PubMed     Abstract available
     
     
     
117. SUEN YN, Pang SWT, Cheung C, Wong TY, et al
     Impact of early negative symptom patterns on the long-term outcomes of patients with first-episode schizophrenia-spectrum disorders: A 12-year follow up study.
     Psychiatry Res. 2023;323:115180.
     PubMed     Abstract available
     
     
     
118. POLETTI M, Pelizza L, Loas G, Azzali S, et al
     Anhedonia and suicidal ideation in young people with early psychosis: Further findings from the 2-year follow-up of the ReARMS program.
     Psychiatry Res. 2023;323:115177.
     PubMed     Abstract available
     
     
     
119. TUCCI AA, Schroeder A, Noel C, Shvetz C, et al
     Social cognition in youth with a first-degree relative with schizophrenia: A systematic scoping review.
     Psychiatry Res. 2023;323:115173.
     PubMed     Abstract available
     
     
     
120. PETKARI E
     Can we really define the effect of psychological interventions on Quality of Life for patients with schizophrenia based on the most recent meta-analysis in the field?
     Psychiatry Res. 2023 Mar 20:115149. doi: 10.1016/j.psychres.2023.115149.
     PubMed    
     
     
     
121. GOUSE BM, Boliver EE, Oblath R, Camacho L, et al
     Cannabis use among patients presenting to the emergency department for psychosis: Associations with restraint use, medication administration, psychiatric hospitalization, and repeat visits.
     Psychiatry Res. 2023;323:115151.
     PubMed     Abstract available
     
     
     
122. AIREY ND, Taylor CDJ, Vikram A, Berry K, et al
     Trauma measures for use with psychosis populations: A systematic review of psychometric properties using COSMIN.
     Psychiatry Res. 2023;323:115163.
     PubMed     Abstract available
     
     
     
123. MEDALIA A, Saperstein A, Javitt DC, Qian M, et al
     Feasibility and clinical utility of using the tone matching test for assessment of early auditory processing in schizophrenia.
     Psychiatry Res. 2023;323:115152.
     PubMed     Abstract available
     
     
     
124. PALMA-ALVAREZ RF, Daigre C, Ros-Cucurull E, Perea-Ortueta M, et al
     Clinical features and factors related to lifetime suicidal ideation and suicide attempts in patients who have had substance-induced psychosis across their lifetime.
     Psychiatry Res. 2023;323:115147.
     PubMed     Abstract available
     
     
     
125. LIN BD, Vermeulen JM, Bolhuis K, Chang X, et al
     Associations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls.
     Psychiatry Res. 2023;323:115143.
     PubMed     Abstract available
     
     
     
126. FIVEL L, Mondino M, Brunelin J, Haesebaert F, et al
     Basic auditory processing and its relationship with symptoms in patients with schizophrenia: A systematic review.
     Psychiatry Res. 2023;323:115144.
     PubMed     Abstract available
     
     
     
127. XIE M, Cai J, Liu Y, Wei W, et al
     Association between childhood trauma and white matter deficits in first-episode schizophrenia.
     Psychiatry Res. 2023;323:115111.
     PubMed     Abstract available
     
     
     
128. VEDDUM L, Gregersen M, Andreassen AK, Knudsen CB, et al
     Social responsiveness in families with parental schizophrenia or bipolar disorder-The Danish High Risk and Resilience Study.
     Psychiatry Res. 2023;323:115140.
     PubMed     Abstract available
     
     
     
129. TAVARES VDO, Rossell SL, Schuch FB, Herring M, et al
     Effects of exercise on cognitive functioning in adults with serious mental illness: A meta analytic review.
     Psychiatry Res. 2023;321:115081.
     PubMed     Abstract available
     
     
     
130. NIZNIKIEWICZ MA
     From communication dysfunction to treatment options in serious mental illness.
     Psychiatry Res. 2023;321:115062.
     PubMed     Abstract available
     
     
     
131. DO KQ
     Bridging the gaps towards precision psychiatry: Mechanistic biomarkers for early detection and intervention.
     Psychiatry Res. 2023;321:115064.
     PubMed     Abstract available
     
     
     
132. DUBOURG L, Kojovic N, Eliez S, Schaer M, et al
     Visual processing of complex social scenes in 22q11.2 deletion syndrome: Relevance for negative symptoms.
     Psychiatry Res. 2023;321:115074.
     PubMed     Abstract available
     
     
     
133. CAI J, Li L, Shao T, Sun M, et al
     Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
     Psychiatry Res. 2023;322:115138.
     PubMed     Abstract available
     
     
     February 2023
134. PONCE-CORREA F, Caqueo-Urizar A, Berrios R, Escobar-Soler C, et al
     Defining recovery in schizophrenia: A review of outcome studies.
     Psychiatry Res. 2023;322:115134.
     PubMed     Abstract available
     
     
     
135. WANG Y, Wang J, Su W, Hu H, et al
     Symptom-circuit mappings of the schizophrenia connectome.
     Psychiatry Res. 2023;323:115122.
     PubMed     Abstract available
     
     
     
136. MA X, Yang WFZ, Zheng W, Li Z, et al
     Neuronal dysfunction in individuals at early stage of schizophrenia, A resting-state fMRI study.
     Psychiatry Res. 2023;322:115123.
     PubMed     Abstract available
     
     
     
137. PERALTA V, de Jalon EG, Moreno-Izco L, Peralta D, et al
     A clinical staging model of psychotic disorders based on a long-term follow-up of first-admission psychosis: A validation study.
     Psychiatry Res. 2023;322:115109.
     PubMed     Abstract available
     
     
     
138. ROMEO B, Willaime L, Rari E, Benyamina A, et al
     Efficacy of 5-HT2A antagonists on negative symptoms in patients with schizophrenia: A meta-analysis.
     Psychiatry Res. 2023;321:115104.
     PubMed     Abstract available
     
     
     
139. STEFFENSEN NL, Hemager N, Bundgaard AF, Gantriis DL, et al
     Affective lability in parents with schizophrenia or bipolar disorder and their co-parents - The Danish High Risk and Resilience Study VIA 7.
     Psychiatry Res. 2023;321:115092.
     PubMed     Abstract available
     
     
     
140. DUDLEY R, Denton S, Mathewson J, Pervez S, et al
     Prevalence of multisensory hallucinations in people at risk of transition to psychosis.
     Psychiatry Res. 2023;322:115091.
     PubMed     Abstract available
     
     
     
141. LUO G, Li Y, Yao C, Li M, et al
     Duration of untreated illness and clinical correlates in first-episode and drug-naive patients with major depressive disorder.
     Psychiatry Res. 2023;320:115056.
     PubMed     Abstract available
     
     
     
142. AAS M, Ueland T, Lagerberg TV, Melle I, et al
     Retrospectively assessed childhood trauma experiences are associated with illness severity in mental disorders adjusted for symptom state.
     Psychiatry Res. 2023;320:115045.
     PubMed     Abstract available
     
     
     
143. OLAYA B, Moneta MV, Plana-Ripoll O, Haro JM, et al
     Association between mental disorders and mortality: A register-based cohort study from the region of Catalonia.
     Psychiatry Res. 2023;320:115037.
     PubMed     Abstract available
     
     
     January 2023
144. KIM AM, Sohn JH
     The impact of the Mental Health Act revision for deinstitutionalization in Korea on the crime rate of people with schizophrenia.
     Psychiatry Res. 2023;321:115089.
     PubMed     Abstract available
     
     
     
145. TAN EJ, Neill E, Kleiner JL, Rossell SL, et al
     Depressive symptoms are specifically related to speech pauses in schizophrenia spectrum disorders.
     Psychiatry Res. 2023;321:115079.
     PubMed     Abstract available
     
     
     
146. BORKENT J, Ioannou M, Folkertsma TS, Wardenaar KJ, et al
     Serum free thiols in recently diagnosed patients with schizophrenia spectrum disorder: A potentially useful biomarker of oxidative stress.
     Psychiatry Res. 2023;321:115075.
     PubMed     Abstract available
     
     
     
147. ESPOSITO CM, Biagianti B, D'Agostino A, Dell'Osso B, et al
     First episode psychosis during the Covid-19 pandemic in Milan, Italy: Diagnostic outcomes at 1-year follow-up.
     Psychiatry Res. 2023;321:115068.
     PubMed     Abstract available
     
     
     
148. SONG M, Liu Y, Zhou J, Shi H, et al
     Potential plasma biomarker panels identification for the diagnosis of first-episode schizophrenia and monitoring antipsychotic monotherapy with the use of metabolomics analyses.
     Psychiatry Res. 2023;321:115070.
     PubMed     Abstract available
     
     
     
149. RICCI V, Ceci F, Di Carlo F, Di Muzio I, et al
     First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness.
     Psychiatry Res. 2023;320:115053.
     PubMed     Abstract available
     
     
     
150. MINOR KS, Lundin NB, Myers EJ, Fernandez-Villardon A, et al
     Automated measures of speech content and speech organization in schizophrenia: Test-retest reliability and generalizability across demographic variables.
     Psychiatry Res. 2023;320:115048.
     PubMed     Abstract available
     
     
     
151. 
     Letter to Editor regarding "Higher rates of first episode psychosis in immigrants admitted in inpatient unit at southwest Spain".
     Psychiatry Res. 2023;322:115016.
     PubMed    
     
     
     
152. KULKARNI J
     Estrogen - A key neurosteroid in the understanding and treatment of mental illness in women.
     Psychiatry Res. 2023;319:114991.
     PubMed     Abstract available
     
     
     
153. MOTA NB
     How can computational tools help to understand language patterns in mental suffering considering social diversity.
     Psychiatry Res. 2023;319:114995.
     PubMed     Abstract available
     
     
     December 2022
154. DELISI LE
     Brain plasticity, language anomalies, genetic risk and the patient with schizophrenia: Trajectory of change over a lifetime. A commentary.
     Psychiatry Res. 2022;320:115034.
     PubMed     Abstract available
     
     
     
155. GALDERISI S
     Negative symptoms of schizophrenia: Trying to answer unanswered research questions.
     Psychiatry Res. 2022;320:115043.
     PubMed     Abstract available
     
     
     
156. LI L, Rami FZ, Lee BM, Kim WS, et al
     Predictors of full recovery in patients with early stage schizophrenia spectrum disorders.
     Psychiatry Res. 2022;320:115035.
     PubMed     Abstract available
     
     
     
157. JIN Y, Tong J, Huang Y, Shi D, et al
     Effectiveness of accelerated intermittent theta burst stimulation for social cognition and negative symptoms among individuals with schizophrenia: A randomized controlled trial.
     Psychiatry Res. 2022;320:115033.
     PubMed     Abstract available
     
     
     
158. PENA-GARIJO J, Lacruz M, Masanet MJ, Palop-Grau A, et al
     Specific facial emotion recognition deficits across the course of psychosis: A comparison of individuals with low-risk, high-risk, first-episode psychosis and multi-episode schizophrenia-spectrum disorders.
     Psychiatry Res. 2022;320:115029.
     PubMed     Abstract available
     
     
     
159. STOROSUM BWC, Mattila T, Wohlfarth TD, Gispen-de Wied CC, et al
     Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies.
     Psychiatry Res. 2022;320:114997.
     PubMed     Abstract available
     
     
     
160. ELLINI S, Romdhane IB, Bougacha D, Abassi A, et al
     COVID-19 induced psychosis: A case report.
     Psychiatry Res. 2022;320:115009.
     PubMed    
     
     
     
161. GARRIDO-TORRES N, Alameda L, Rocha-Gonzalez I, Canal-Rivero M, et al
     Response to the letter to editor regarding "Higher rates of first episode psychosis in immigrants admitted in inpatient unit at southwest Spain".
     Psychiatry Res. 2022;322:115008.
     PubMed    
     
     
     
162. MANNARINI S, Taccini F, Sato I, Rossi AA, et al
     Understanding stigma toward schizophrenia.
     Psychiatry Res. 2022;318:114970.
     PubMed     Abstract available
     
     
     
163. SOMMER IE, N de Boer J
     How to reap the benefits of language for psychiatry.
     Psychiatry Res. 2022;318:114932.
     PubMed     Abstract available
     
     
     November 2022
164. ROSEN RL, Ramasubramani RS, Benowitz NL, Gandhi KK, et al
     Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder.
     Psychiatry Res. 2022;319:114989.
     PubMed     Abstract available
     
     
     
165. BASSETT AS
     Clinical genetics of schizophrenia and related neuropsychiatric disorders.
     Psychiatry Res. 2022;319:114992.
     PubMed     Abstract available
     
     
     
166. DUDLEY R, Watson F, O'Grady L, Aynsworth C, et al
     Prevalence and nature of multi-sensory and multi-modal hallucinations in people with first episode psychosis.
     Psychiatry Res. 2022;319:114988.
     PubMed     Abstract available
     
     
     
167. LAHTI AC
     Discovery of early schizophrenia through neuroimaging.
     Psychiatry Res. 2022;322:114993.
     PubMed     Abstract available
     
     
     
168. CELLA M, Sedgwick O, Lawrence M, Grant N, et al
     Evaluating the mechanisms of social cognition intervention in schizophrenia: A proof-of-concept trial.
     Psychiatry Res. 2022;319:114963.
     PubMed     Abstract available
     
     
     
169. TAO TJ, Hui CLM, Hui PWM, Ho ECN, et al
     Working memory deterioration as an early warning sign for relapse in remitted psychosis: A one-year naturalistic follow-up study.
     Psychiatry Res. 2022;319:114976.
     PubMed     Abstract available
     
     
     
170. XIE Y, Guan M, Cai Y, Wang Z, et al
     Impact of low-frequency repetitive transcranial magnetic stimulation on functional network connectivity in schizophrenia patients with auditory verbal hallucinations.
     Psychiatry Res. 2022;320:114974.
     PubMed     Abstract available
     
     
     
171. GOODING DC
     Social anhedonia and other indicators of risk for schizophrenia: Theory and inquiry.
     Psychiatry Res. 2022;319:114966.
     PubMed     Abstract available
     
     
     
172. CHA M, Al-Chalabi N, Qian J, Chaudhary Z, et al
     Concordance between the Columbia-Suicide Severity Rating Scale and Beck Scale for Suicide Ideation in assessing suicide behaviour in young adults with schizophrenia spectrum disorders.
     Psychiatry Res. 2022;319:114965.
     PubMed     Abstract available
     
     
     
173. LV H, Li J, Gao K, Zeng L, et al
     Identification of genetic loci that overlap between schizophrenia and metabolic syndrome.
     Psychiatry Res. 2022;318:114947.
     PubMed     Abstract available
     
     
     
174. RUIZ-DELGADO I, Moreno-Kustner B, Garcia-Medina M, Barrigon ML, et al
     Is Metacognitive Training effective for improving neurocognitive function in patients with a recent onset of psychosis?
     Psychiatry Res. 2022;318:114941.
     PubMed     Abstract available
     
     
     
175. SCHWAB SG
     Genetic variation and susceptibility to schizophrenia: Work in progress.
     Psychiatry Res. 2022;318:114949.
     PubMed     Abstract available
     
     
     
176. ZHANG Q, Huo JH, Guo L, Wang L, et al
     Common and rare variants within SP4 exert distinct molecular mechanisms contributing to the risk of schizophrenia.
     Psychiatry Res. 2022;318:114948.
     PubMed    
     
     
     
177. LU W, Srijeyanthan J, Mueser KT, Yanos PT, et al
     Predictors of undocumented PTSD in persons using public mental health services.
     Psychiatry Res. 2022;317:114892.
     PubMed     Abstract available
     
     
     
178. KIM WS, Heo DW, Shen J, Tsogt U, et al
     Altered functional connectivity in psychotic disorder not otherwise specified.
     Psychiatry Res. 2022;317:114871.
     PubMed     Abstract available
     
     
     
179. LANGLOIS T, Sanchez-Rodriguez R, Bourcier A, Lamy P, et al
     "Accept voices(c)" group intervention for the management of auditory verbal hallucinations-results at 6 and 12 months.
     Psychiatry Res. 2022;317:114860.
     PubMed     Abstract available
     
     
     
180. RIHAL V, Khan H, Kaur A, Singh TG, et al
     Therapeutic and mechanistic intervention of vitamin D in neuropsychiatric disorders.
     Psychiatry Res. 2022;317:114782.
     PubMed     Abstract available
     
     
     October 2022
181. ZHANG T, Zeng J, Wei Y, Ye J, et al
     Changes in inflammatory balance correlates with conversion to psychosis among individuals at clinical high-risk: A prospective cohort study.
     Psychiatry Res. 2022;318:114938.
     PubMed     Abstract available
     
     
     
182. SCHELIGA S, Schwank R, Scholle R, Habel U, et al
     A neural mechanism underlying predictive visual motion processing in patients with schizophrenia.
     Psychiatry Res. 2022;318:114934.
     PubMed     Abstract available
     
     
     
183. CUESTA MJ, Sanchez-Torres AM, Moreno-Izco L, Garcia de Jalon E, et al
     Neurocognitive correlates of the varied domains of outcomes at 20 year follow-up of first-episode psychosis.
     Psychiatry Res. 2022;318:114933.
     PubMed     Abstract available
     
     
     
184. ENDRES D, Lerchenmuller V, Runge K, von Zedtwitz K, et al
     Anti-astrocytic autoantibody patterns in the cerebrospinal fluid of patients with depression and psychosis.
     Psychiatry Res. 2022;317:114905.
     PubMed     Abstract available
     
     
     
185. GIZDIC A, Baxter T, Barrantes-Vidal N, Park S, et al
     Loneliness and psychosocial predictors of psychosis-proneness during COVID-19: Preliminary findings from Croatia.
     Psychiatry Res. 2022;317:114900.
     PubMed     Abstract available
     
     
     
186. DEAN B, Thomas EHX, Bozaoglu K, Tan EJ, et al
     Evidence that a working memory cognitive phenotype within schizophrenia has a unique underlying biology.
     Psychiatry Res. 2022;317:114873.
     PubMed     Abstract available
     
     
     
187. PELIZZA L, Quattrone E, Leuci E, Paulillo G, et al
     Anxious-depressive symptoms after a first episode of schizophrenia: Response to treatment and psychopathological considerations from the 2-year "Parma Early Psychosis" program.
     Psychiatry Res. 2022;317:114887.
     PubMed     Abstract available
     
     
     
188. BARLATI S, Nibbio G, Bianchi F, Gigli EBL, et al
     Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting.
     Psychiatry Res. 2022;317:114878.
     PubMed     Abstract available
     
     
     
189. DOKUZ G, Kani AS, Uysal O, Kuscu MK, et al
     The impact of childhood trauma and daily life experiences on emotional and psychotic symptom intensity in psychosis: An experience sampling study.
     Psychiatry Res. 2022;317:114872.
     PubMed     Abstract available
     
     
     September 2022
190. UPTHEGROVE R
     From co-morbidity to transdiagnostic potential and novel immunotherapies for psychosis.
     Psychiatry Res. 2022;317:114866.
     PubMed     Abstract available
     
     
     
191. MORITZ S, Goritz AS, Franz C, Sibilis A, et al
     Whodunit - A novel video-based task for the measurement of jumping to conclusions in the schizophrenia spectrum.
     Psychiatry Res. 2022;317:114862.
     PubMed     Abstract available
     
     
     
192. WALKER E
     The permeable boundary between biological and psychological processes in the origins of psychosis.
     Psychiatry Res. 2022;317:114853.
     PubMed     Abstract available
     
     
     
193. MALASPINA D
     A sisters search for the seeds of psychosis.
     Psychiatry Res. 2022;317:114846.
     PubMed     Abstract available
     
     
     
194. SNELLEKSZ M, Rossell SL, Gibbons A, Nithianantharajah J, et al
     Evidence that the frontal pole has a significant role in the pathophysiology of schizophrenia.
     Psychiatry Res. 2022;317:114850.
     PubMed     Abstract available
     
     
     
195. YAO L, Liu H, Tian X
     Medication adherence among community-dwelling schizophrenia patients during the COVID-19 pandemic: A cross-sectional study.
     Psychiatry Res. 2022;317:114841.
     PubMed     Abstract available
     
     
     August 2022
196. KOOPOWITZ SM, Cotton SM, Uhlmann A, Thomas KGF, et al
     Executive function in methamphetamine users with and without psychosis.
     Psychiatry Res. 2022;317:114820.
     PubMed     Abstract available
     
     
     
197. BIZUMIC B, Gunningham B, Christensen BK
     Prejudice towards people with mental illness, schizophrenia, and depression among mental health professionals and the general population.
     Psychiatry Res. 2022;317:114817.
     PubMed     Abstract available
     
     
     
198. EATON WW, Rodriguez KM, Thomas MA, Johnson J, et al
     Immunologic profiling in schizophrenia and rheumatoid arthritis.
     Psychiatry Res. 2022;317:114812.
     PubMed     Abstract available
     
     
     
199. BARANOVA A, Cao H, Zhang F
     Severe COVID-19 increases the risk of schizophrenia.
     Psychiatry Res. 2022;317:114809.
     PubMed     Abstract available
     
     
     
200. MCCARTHY JM, Wood AJ, Shinners MG, Heinrich H, et al
     Pilot development and feasibility of telehealth Community Reinforcement and Family Training (CRAFT) for early psychosis and substance use.
     Psychiatry Res. 2022;317:114804.
     PubMed     Abstract available
     
     
     
201. HU M, Xia Y, Zong X, Sweeney JA, et al
     Risperidone-induced changes in DNA methylation in peripheral blood from first-episode schizophrenia patients parallel changes in neuroimaging and cognitive phenotypes.
     Psychiatry Res. 2022;317:114789.
     PubMed     Abstract available
     
     
     
202. LYNCH DA, Brown M, Saperstein A, Stefancic A, et al
     Assessing metamotivation in schizophrenia: A pilot study of the Brief Regulation of Motivation Scale (BRoMS).
     Psychiatry Res. 2022;317:114799.
     PubMed     Abstract available
     
     
     
203. LI Z, Chen X
     Comprehensive analysis of shared genetic loci between hippocampal volume and schizophrenia.
     Psychiatry Res. 2022;316:114795.
     PubMed     Abstract available
     
     
     
204. TIKKANEN V, Siira V, Wahlberg KE, Hakko H, et al
     Deficits in adolescent social functioning, dysfunctional family processes and genetic risk for schizophrenia spectrum disorders as risk factors for later psychiatric morbidity of adoptees.
     Psychiatry Res. 2022;316:114793.
     PubMed     Abstract available
     
     
     
205. LIU CM, Liu CC, Hsieh MH, Hwang TJ, et al
     The plasma level of complement component 4A decreases with aripiprazole treatment in patients with early psychosis.
     Psychiatry Res. 2022;316:114775.
     PubMed     Abstract available
     
     
     
206. HERPERTZ J, Richter MF, Barkhau C, Storck M, et al
     Symptom monitoring based on digital data collection during inpatient treatment of schizophrenia spectrum disorders - A feasibility study.
     Psychiatry Res. 2022;316:114773.
     PubMed     Abstract available
     
     
     
207. CAI H, Zeng C, Zhang X, Liu Y, et al
     Diminished treatment response in relapsed versus first-episode schizophrenia as revealed by a panel of blood-based biomarkers: A combined cross-sectional and longitudinal study.
     Psychiatry Res. 2022;316:114762.
     PubMed     Abstract available
     
     
     
208. KOOL L, Oranje B, Meijs H, De Wilde B, et al
     Event-related potentials and use of psychotropic medication in major psychiatric disorders.
     Psychiatry Res. 2022;314:114637.
     PubMed     Abstract available
     
     
     
209. PUJOL N, Berge D, Mane A, Bioque M, et al
     The influence of modifiable cardiovascular risk factors on cognition, functioning, and inflammatory markers in first-episode psychosis: Results from a 2-year follow-up study.
     Psychiatry Res. 2022;316:114760.
     PubMed     Abstract available
     
     
     July 2022
210. SALEHI A, Namaei P, TaghaviZanjani F, Bagheri S, et al
     Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
     Psychiatry Res. 2022;316:114737.
     PubMed     Abstract available
     
     
     
211. DESAI SS, Nguyen AL, Bernstein GA
     Letter to editor: Case report of long COVID-19 with psychosis in a child.
     Psychiatry Res. 2022;316:114743.
     PubMed    
     
     
     
212. SEEMAN MV
     Sex/Gender differences in schizophrenia: Thinking back and thinking forward.
     Psychiatry Res. 2022;316:114738.
     PubMed     Abstract available
     
     
     
213. DADERWAL MC, Sreeraj VS, Suhas S, Rao NP, et al
     Montreal Cognitive Assessment (MoCA) and Digit Symbol Substitution Test (DSST) as a screening tool for evaluation of cognitive deficits in schizophrenia.
     Psychiatry Res. 2022;316:114731.
     PubMed     Abstract available
     
     
     
214. GALLIOT G, Sanchez-Rodriguez R, Belloc A, Phulpin H, et al
     Is clinical insight a determinant factor of subjective recovery in persons living with schizophrenia or schizoaffective disorders?
     Psychiatry Res. 2022;316:114726.
     PubMed     Abstract available
     
     
     
215. PARK HJ, Kang WS, Oh M, Kim JW, et al
     Association of the promoter haplotype in CDK5 gene with schizophrenia in a Korean population.
     Psychiatry Res. 2022;316:114723.
     PubMed    
     
     
     
216. RIBOLSI M, Albergo G, Fiori Nastro F, Pelle M, et al
     Autistic symptomatology in UHR patients: A preliminary report.
     Psychiatry Res. 2022;313:114634.
     PubMed     Abstract available
     
     
     
217. NGUYEN T, Frayne J, Watson S, Lebedevs T, et al
     Long-acting injectable antipsychotic treatment during pregnancy: Outcomes for women at a tertiary maternity hospital.
     Psychiatry Res. 2022;313:114614.
     PubMed     Abstract available
     
     
     June 2022
218. DIAGO M, Vila-Badia R, Serra-Arumi C, Butjosa A, et al
     Emotional abuse and perceived stress: The most relevant factors in suicide behavior in first-episode psychosis patients.
     Psychiatry Res. 2022;315:114699.
     PubMed     Abstract available
     
     
     
219. JEREMIAN R, Malinowski A, Chaudhary Z, Srivastava A, et al
     Epigenetic age dysregulation in individuals with bipolar disorder and schizophrenia.
     Psychiatry Res. 2022;315:114689.
     PubMed     Abstract available
     
     
     
220. RAMAIN J, Conus P, Golay P
     Grouping affective psychoses in early intervention: Justification for specific treatment guidelines.
     Psychiatry Res. 2022;314:114690.
     PubMed     Abstract available
     
     
     
221. ZARBO C, Agosta S, Casiraghi L, De Novellis A, et al
     Assessing adherence to and usability of Experience Sampling Method (ESM) and actigraph in patients with Schizophrenia Spectrum Disorder: A mixed-method study.
     Psychiatry Res. 2022;314:114675.
     PubMed     Abstract available
     
     
     May 2022
222. LI Z, Li X, Jin M, Liu Y, et al
     Identification of potential biomarkers and their correlation with immune infiltration cells in schizophrenia using combinative bioinformatics strategy.
     Psychiatry Res. 2022;314:114658.
     PubMed     Abstract available
     
     
     
223. SHIMADA T, Ito S, Makabe A, Yamanushi A, et al
     Aerobic exercise and cognitive functioning in schizophrenia: An updated systematic review and meta-analysis.
     Psychiatry Res. 2022;314:114656.
     PubMed     Abstract available
     
     
     
224. KIRSCHENBAUM MA, Lopez LV, de Filippis R, Ali AF, et al
     Validation of a novel Psychosis-Implicit Association Test (P-IAT) as a diagnostic support tool.
     Psychiatry Res. 2022;314:114647.
     PubMed     Abstract available
     
     
     
225. BHATTACHARYYA U, Bhatia T, Deshpande SN, Thelma BK, et al
     Genetic variations in evolutionary accelerated regions disrupt cognition in schizophrenia.
     Psychiatry Res. 2022;314:114586.
     PubMed     Abstract available
     
     
     
226. XU L, Hao D, Wei Y, Cui H, et al
     Effect of cognitive insight on clinical insight from pre-morbid to early psychosis stages.
     Psychiatry Res. 2022;313:114613.
     PubMed     Abstract available
     
     
     
227. CAO X, Chen S, Xu H, Wang Q, et al
     Global functioning, cognitive function, psychopathological symptoms in untreated patients with first-episode schizophrenia: A cross-sectional study.
     Psychiatry Res. 2022;313:114616.
     PubMed     Abstract available
     
     
     
228. LONG J, Tian L, Baranova A, Cao H, et al
     Convergent lines of evidence supporting involvement of NFKB1 in schizophrenia.
     Psychiatry Res. 2022;312:114588.
     PubMed     Abstract available
     
     
     
229. KATZ IR, Szymanski BR, Marder SR, Shotwell A, et al
     Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications.
     Psychiatry Res. 2022;313:114590.
     PubMed     Abstract available
     
     
     April 2022
230. THAI H, Robertson C, Friberg L, Hatko A, et al
     WHODAS 2.0: Associations of functional disability with sex, age, and length of care in outpatients with schizophrenia-spectrum disorders.
     Psychiatry Res. 2022;313:114583.
     PubMed     Abstract available
     
     
     
231. MARTINS PS, Caldas F, Oliveira C, Mota J, et al
     A 10-year mirror-image study of effectiveness and cost of long-acting paliperidone palmitate injectable in patients with schizophrenia or schizoaffective disorder.
     Psychiatry Res. 2022;312:114581.
     PubMed     Abstract available
     
     
     
232. LI X, Yuan X, Pang L, Zhang S, et al
     nThe effect of serum lipids and short-chain fatty acids on cognitive functioning in drug-naive, first episode schizophrenia patients.
     Psychiatry Res. 2022;313:114582.
     PubMed     Abstract available
     
     
     
233. XU Y, Cai Z, Fang C, Zheng J, et al
     Impact of aerobic exercise on cognitive function in patients with schizophrenia during daily care: A meta-analysis.
     Psychiatry Res. 2022;312:114560.
     PubMed     Abstract available
     
     
     
234. OUYANG H, Huang M, Chen S, Wu X, et al
     Peripheral lower triiodothyronine levels related to interleukin-6 in patients with first-episode schizophrenia.
     Psychiatry Res. 2022;312:114546.
     PubMed    
     
     
     
235. WELCH KG, Stiles BJ, Palsson OS, Meyer-Kalos PS, et al
     The use of diary methods to evaluate daily experiences in first-episode psychosis.
     Psychiatry Res. 2022;312:114548.
     PubMed     Abstract available
     
     
     
236. GONZALEZ-RODRIGUEZ A, Monreal JA, Porras-Segovia A, Cervilla JA, et al
     Psychometric instruments for the assessment of depressive symptoms in patients with delusional disorder: A systematic review.
     Psychiatry Res. 2022;310:114435.
     PubMed     Abstract available
     
     
     March 2022
237. JAISWAL N, Kar SK, Gupta PK
     Comments on "High frequency repetitive transcranial magnetic stimulation of dorsomedial prefrontal cortex for negative symptoms in patients with schizophrenia: A double-blind, randomized controlled trial".
     Psychiatry Res. 2022;312:114532.
     PubMed    
     
     
     
238. PANDOLFO G, Genovese G, Bruno A, Campolo D, et al
     Advanced glycation end-products and advanced oxidation protein products in schizophrenia.
     Psychiatry Res. 2022;311:114527.
     PubMed     Abstract available
     
     
     
239. LI J, Zhang X, Jiang J, Zhang B, et al
     Comparison of electroconvulsive therapy and magnetic seizure therapy in schizophrenia: Structural changes/neuroplasticity.
     Psychiatry Res. 2022;312:114523.
     PubMed     Abstract available
     
     
     
240. BORNHEIMER LA, Li Verdugo J, Holzworth J, Im V, et al
     Modifying a cognitive behavioral suicide prevention treatment for adults with schizophrenia spectrum disorders in community mental health.
     Psychiatry Res. 2022;311:114505.
     PubMed     Abstract available
     
     
     
241. XU X, Shao G, Zhang X, Hu Y, et al
     The efficacy of nutritional supplements for the adjunctive treatment of schizophrenia in adults: A systematic review and network meta-analysis.
     Psychiatry Res. 2022;311:114500.
     PubMed     Abstract available
     
     
     
242. RAMMOUZ I, Bouri S, Merzouki M, Berraho MA, et al
     Reliability of self-report of cannabis use among patients with schizophrenia.
     Psychiatry Res. 2022;311:114491.
     PubMed    
     
     
     
243. KEMPPAINEN A, Lindgren M, Suvisaari J, Kieseppa T, et al
     Adverse childhood experiences and social and occupational functioning in first-episode psychosis - A one year follow - up.
     Psychiatry Res. 2022;311:114502.
     PubMed    
     
     
     
244. MUNIR K, Oner O, Kerala C, Rustamov I, et al
     Social distance and stigma towards persons with serious mental illness among medical students in five European Central Asia countries.
     Psychiatry Res. 2022;309:114409.
     PubMed     Abstract available
     
     
     February 2022
245. GOHARI E, Moore RC, Depp CA, Ackerman RA, et al
     Momentary severity of psychotic symptoms predicts overestimation of competence in domains of everyday activities and work in schizophrenia: An ecological momentary assessment study.
     Psychiatry Res. 2022;310:114487.
     PubMed     Abstract available
     
     
     
246. LIU Y, Jia LN, Wu H, Jiang W, et al
     Adjuvant electroconvulsive therapy with antipsychotics is associated with improvement in auditory mismatch negativity in schizophrenia.
     Psychiatry Res. 2022;311:114484.
     PubMed    
     
     
     
247. COWAN T, Cohen AS, Raugh IM, Strauss GP, et al
     Ambulatory audio and video recording for digital phenotyping in schizophrenia: Adherence & data usability.
     Psychiatry Res. 2022;311:114485.
     PubMed     Abstract available
     
     
     
248. SANTESTEBAN-ECHARRI O, Sandel D, Liu L, Bearden CE, et al
     Family history of psychosis in youth at clinical high risk: A replication study.
     Psychiatry Res. 2022;311:114480.
     PubMed     Abstract available
     
     
     
249. MORIKAWA R, Watanabe Y, Igeta H, Arta RK, et al
     Novel missense SETD1A variants in Japanese patients with schizophrenia: Resequencing and association analysis.
     Psychiatry Res. 2022;310:114481.
     PubMed     Abstract available
     
     
     
250. RODRIGUEZ M, Knizkova K, Kerkova B, Sironova A, et al
     The relationships between cognitive reserve, cognitive functioning and quality of life in first-episode schizophrenia spectrum disorders.
     Psychiatry Res. 2022;310:114479.
     PubMed     Abstract available
     
     
     
251. LEE HS, Rast C, Shenoy S, Dean D, et al
     A meta-analytic review of transcranial direct current stimulation (tDCS) on general psychopathology symptoms of schizophrenia; immediate improvement followed by a return to baseline.
     Psychiatry Res. 2022;310:114471.
     PubMed     Abstract available
     
     
     
252. SONG W, Lin GN, Yu S, Zhao M, et al
     Genome-wide identification of the shared genetic basis of cannabis and cigarette smoking and schizophrenia implicates NCAM1 and neuronal abnormality.
     Psychiatry Res. 2022;310:114453.
     PubMed     Abstract available
     
     
     
253. TAN EJ, Toh WL, Rossell SL
     Examining relationships between state and trait psychotic symptoms and quality of life in schizophrenia spectrum disorders.
     Psychiatry Res. 2022;310:114450.
     PubMed     Abstract available
     
     
     
254. LOPEZ-NAVARRO E, Fonseca-Pedrero E, Errasti J, Al-Halabi S, et al
     Mindfulness improves theory of mind in people experiencing psychosis: A pilot randomized clinical trial.
     Psychiatry Res. 2022;310:114440.
     PubMed     Abstract available
     
     
     
255. GOH XX, Tang PY, Tee SF
     Effects of antipsychotics on antioxidant defence system in patients with schizophrenia: A meta-analysis.
     Psychiatry Res. 2022;309:114429.
     PubMed     Abstract available
     
     
     
256. SCHWARTZ EK, Le TP, Cohen AS
     Sharing positive events: Ecological momentary assessment of emotion regulation via social capitalization in schizotypy.
     Psychiatry Res. 2022;308:114377.
     PubMed     Abstract available
     
     
     
257. GROENMAN AP, van der Werf S, Geurts HM
     Subjective cognition in adults with common psychiatric classifications; a systematic review.
     Psychiatry Res. 2022;308:114374.
     PubMed     Abstract available
     
     
     January 2022
258. JEONG JH, Kim SW, Lee BJ, Kim JJ, et al
     The factor structure and clinical utility of clinician-rated dimensions of psychosis symptom severity in patients with recent-onset psychosis: Results of a 1-year longitudinal follow-up prospective cohort study.
     Psychiatry Res. 2022;310:114420.
     PubMed     Abstract available
     
     
     
259. BARTOLI F, Cavaleri D, Callovini T, Riboldi I, et al
     Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study.
     Psychiatry Res. 2022;309:114405.
     PubMed     Abstract available
     
     
     
260. LUNDIN NB, Jones MN, Myers EJ, Breier A, et al
     Semantic and phonetic similarity of verbal fluency responses in early-stage psychosis.
     Psychiatry Res. 2022;309:114404.
     PubMed     Abstract available
     
     
     
261. XIE Y, He Y, Guan M, Wang Z, et al
     Low-frequency rTMS treatment alters the topographical organization of functional brain networks in schizophrenia patients with auditory verbal hallucination.
     Psychiatry Res. 2022;309:114393.
     PubMed     Abstract available
     
     
     
262. RAULT O, Lamothe H, Pelissolo A
     Therapeutic use of virtual reality relaxation in schizophrenia: A pilot study.
     Psychiatry Res. 2022;309:114389.
     PubMed     Abstract available
     
     
     
263. VERDOUX H, Sibert A, Quiles C
     Trauma and resistance to antipsychotic treatment in schizophrenia: A narrative review.
     Psychiatry Res. 2022;309:114392.
     PubMed     Abstract available
     
     
     
264. MORAN LV, Tsang ES, Ongur D, Hsu J, et al
     Geographical variation in hospitalization for psychosis associated with cannabis use and cannabis legalization in the United States: Submit to: Psychiatry Research.
     Psychiatry Res. 2022;308:114387.
     PubMed     Abstract available
     
     
     
265. SINGH A, Kumar V, Pathak H, Jacob AA, et al
     Effect of antipsychotic dose reduction on cognitive function in schizophrenia.
     Psychiatry Res. 2022;308:114383.
     PubMed     Abstract available
     
     
     
266. GANDHI A, Mote J, Fulford D
     A transdiagnostic meta-analysis of physical and social Anhedonia in major depressive disorder and schizophrenia spectrum disorders.
     Psychiatry Res. 2022;309:114379.
     PubMed     Abstract available
     
     
     December 2021
267. LABONTE C, Zhand N, Park A, Harvey PD, et al
     Complete blood count inflammatory markers in treatment-resistant schizophrenia: Evidence of association between treatment responsiveness and levels of inflammation.
     Psychiatry Res. 2021;308:114382.
     PubMed     Abstract available
     
     
     
268. GICAS KM, Parmar PK, Fabiano GF, Mashhadi F, et al
     Substance-induced psychosis and cognitive functioning: A systematic review.
     Psychiatry Res. 2021;308:114361.
     PubMed     Abstract available
     
     
     
269. GARRIDO-TORRES N, Suarez-Suarez ML, Rocha-Gonzalez I, Alameda L, et al
     Higher rates of first episode psychosis in immigrants admitted in inpatient unit at southwest Spain.
     Psychiatry Res. 2021;308:114352.
     PubMed     Abstract available
     
     
     
270. VERU F, MacDonald K, Malla A, Pruessner M, et al
     The effects of childhood adversity on treatment delays and its components in first-episode psychosis.
     Psychiatry Res. 2021;308:114341.
     PubMed     Abstract available
     
     
     
271. LAVAUD P, McMahon K, Sanchez Rico M, Hanon C, et al
     Long-term care utilization within older adults with schizophrenia: Associated factors in a multicenter study.
     Psychiatry Res. 2021;308:114339.
     PubMed     Abstract available
     
     
     
272. LIU X, Wang D, Fan R, Wang R, et al
     Life expectancy and potential years of life lost for schizophrenia in western China.
     Psychiatry Res. 2021;308:114330.
     PubMed     Abstract available
     
     
     
273. LOCKWOOD L, Miller B, Youssef NA
     Epigenetics and first-episode psychosis: A systematic review.
     Psychiatry Res. 2021;307:114325.
     PubMed     Abstract available
     
     
     
274. THOMPSON EC, Visser KF, Schiffman J, Spirito A, et al
     Preliminary evidence supporting the practice of psychosis-risk screening within an inpatient psychiatric setting serving adolescents.
     Psychiatry Res. 2021;307:114322.
     PubMed     Abstract available
     
     
     
275. LEE S, Schwartz S
     Adherence and persistence to long-acting injectable dopamine receptor blocking agent therapy in the United States: A systematic review and meta-analysis of cohort studies.
     Psychiatry Res. 2021;306:114277.
     PubMed     Abstract available
     
     
     November 2021
276. LOCH AA, Mota NB, Rossler W, Gattaz WF, et al
     Exacerbation of psychosis risk during the COVID-19 pandemic: The disproportionate impact on the lower income population.
     Psychiatry Res. 2021;307:114319.
     PubMed    
     
     
     
277. ALLIENDE LM, Czepielewski LS, Aceituno D, Castaneda CP, et al
     Gender, age and geographical representation over the past 50 years of schizophrenia research.
     Psychiatry Res. 2021;307:114279.
     PubMed     Abstract available
     
     
     
278. FERNANDEZ DK, Deane FP, Vella SA
     Effects of online continuum and categorical belief manipulations on schizophrenia stigma, help-seeking, and help-provision.
     Psychiatry Res. 2021;307:114293.
     PubMed     Abstract available
     
     
     
279. CHEN S, Tang Y, Fan X, Qiao Y, et al
     The role of white matter abnormality in the left anterior corona radiata: In relation to formal thought disorder in patients with schizophrenia.
     Psychiatry Res. 2021;307:114302.
     PubMed     Abstract available
     
     
     
280. GOU N, Xiang Y, Zhou J, Zhang S, et al
     Identification of violent patients with schizophrenia using a hybrid machine learning approach at the individual level.
     Psychiatry Res. 2021;306:114294.
     PubMed     Abstract available
     
     
     
281. LAI M, Hegde R, Kelly S, Bannai D, et al
     Investigating sleep spindle density and schizophrenia: A meta-analysis.
     Psychiatry Res. 2021;307:114265.
     PubMed     Abstract available
     
     
     
282. BARR SM, Roberts D, Thakkar KN
     Psychosis in transgender and gender non-conforming individuals: A review of the literature and a call for more research.
     Psychiatry Res. 2021;306:114272.
     PubMed     Abstract available
     
     
     
283. LYU J, Zhang J
     Suicide means, timing, intent and behavior characteristics of the suicides with schizophrenia.
     Psychiatry Res. 2021;306:114267.
     PubMed     Abstract available
     
     
     
284. RUSSO M, Consoli S, De Rosa MA, Calisi D, et al
     A case of Sars-Cov-2-related mania with prominent psychosis>.
     Psychiatry Res. 2021;306:114266.
     PubMed    
     
     
     
285. GALLOS IK, Mantonakis L, Spilioti E, Kattoulas E, et al
     The relation of integrated psychological therapy to resting state functional brain connectivity networks in patients with schizophrenia.
     Psychiatry Res. 2021;306:114270.
     PubMed     Abstract available
     
     
     
286. SANTOS MJ, Ferreira TF, Sequeira M, Trancas B, et al
     Chronic hallucinatory psychosis presenting with olfactory hallucinations: A case report.
     Psychiatry Res. 2021;305:114262.
     PubMed    
     
     
     
287. SAHYOUNI C, Hefazi E
     Clozapine induced pericarditis: A case report.
     Psychiatry Res. 2021;305:114250.
     PubMed     Abstract available
     
     
     
288. SHROITMAN NK, Peles E, Even-Tov S, Schreiber S, et al
     False-positive fentanyl screening kit results during treatment with long term injectable risperidone (Risperdal-Consta).
     Psychiatry Res. 2021;305:114246.
     PubMed     Abstract available
     
     
     
289. RICHARDSON N, Greenway SC, Bousman CA
     Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review.
     Psychiatry Res. 2021;305:114247.
     PubMed     Abstract available
     
     
     
290. BRASSO C, Cisotto M, Ghirardini C, Pennazio F, et al
     Accuracy of self-reported adherence and therapeutic drug monitoring in a psychiatric emergency ward.
     Psychiatry Res. 2021;305:114214.
     PubMed     Abstract available
     
     
     
291. GROT S, Giguere CE, Smine S, Mongeau-Perusse V, et al
     Converting scores between the PANSS and SAPS/SANS beyond the positive/negative dichotomy.
     Psychiatry Res. 2021;305:114199.
     PubMed     Abstract available
     
     
     
292. MILLER BJ, McCall WV, McEvoy JP, Lu XY, et al
     Insomnia and inflammation in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
     Psychiatry Res. 2021;305:114195.
     PubMed     Abstract available
     
     
     October 2021
293. MENON V, Suhas S, Sethi MIS, Varadharajan N, et al
     Comments on the paper published by Lyu et al on Risk Factors for Suicide in People with Schizophrenia.
     Psychiatry Res. 2021;306:114255.
     PubMed    
     
     
     
294. DAMIANO RF, Avrichir BS, Melzer-Ribeiro DL, Sallet PC, et al
     Which are the best evidence-based therapeutic options for clozapine and ECT resistant schizophrenia? A case-report.
     Psychiatry Res. 2021;305:114248.
     PubMed     Abstract available
     
     
     
295. PAWELCZYK A, Lojek E, Radek M, Pawelczyk T, et al
     Prosodic deficits and interpersonal difficulties in patients with schizophrenia.
     Psychiatry Res. 2021;306:114244.
     PubMed     Abstract available
     
     
     
296. LUO X, Zhang L, Zhang J, Chen H, et al
     Changes in the cognitive function of Chinese college students with a clinical high risk of psychosis.
     Psychiatry Res. 2021;305:114242.
     PubMed     Abstract available
     
     
     
297. CLAYSON PE, Molina JL, Joshi YB, Thomas ML, et al
     Evaluation of the frequency following response as a predictive biomarker of response to cognitive training in schizophrenia.
     Psychiatry Res. 2021;305:114239.
     PubMed     Abstract available
     
     
     
298. JIANG W, Rootes-Murdy K, Chen J, Bizzozero NIP, et al
     Multivariate alterations in insula - Medial prefrontal cortex linked to genetics in 12q24 in schizophrenia.
     Psychiatry Res. 2021;306:114237.
     PubMed     Abstract available
     
     
     
299. SANCHEZ MC, Escurriola MF, Sanmartin MIF, Solntseva I, et al
     Cardiovascular disease and mortality in people with schizophrenia or antipsychotic treatment: A cohort study in primary care.
     Psychiatry Res. 2021;306:114233.
     PubMed     Abstract available
     
     
     
300. BRYCE S, Zbukvic I, Wood SJ, Allott K, et al
     Cognitive remediation to address impairment in schizophrenia: Moving beyond effectiveness and toward implementation.
     Psychiatry Res. 2021;305:114232.
     PubMed    
     
     
     
301. MINICHINO A, Singh F, Pineda J, Friederich E, et al
     Corrigendum to 'Biological Motion induced mu suppression is reduced in Early Psychosis (EP) patients with active negative symptoms and Autism Spectrum Disorders (ASD)' [Psychiatry Research 238 (2016) 374-377].
     Psychiatry Res. 2021;306:114177.
     PubMed    
     
     
     
302. SARZYNSKA-WAWER J, Wawer A, Pawlak A, Szymanowska J, et al
     Detecting formal thought disorder by deep contextualized word representations.
     Psychiatry Res. 2021;304:114135.
     PubMed     Abstract available
     
     
     September 2021
303. LUDTKE T, Ruegg N, Moritz S, Berger T, et al
     Insight and the number of completed modules predict a reduction of positive symptoms in an Internet-based intervention for people with psychosis.
     Psychiatry Res. 2021;306:114223.
     PubMed     Abstract available
     
     
     
304. ZOU DS, Cowan HR, Azis M, Mittal VA, et al
     Reciprocal Social Behavior and Related Social Outcomes in Individuals at Clinical High Risk for Psychosis.
     Psychiatry Res. 2021;306:114224.
     PubMed     Abstract available
     
     
     
305. SRIVASTAVA A, Dada O, Qian J, Al-Chalabi N, et al
     Epigenetics of Schizophrenia.
     Psychiatry Res. 2021;305:114218.
     PubMed     Abstract available
     
     
     
306. FERNANDO R, Gan L, Xiao J, Yun Y, et al
     Hyperprolactinemia induced by brexpiprazole in patients with schizophrenia: A case report.
     Psychiatry Res. 2021;305:114215.
     PubMed    
     
     
     
307. HOMMAN LE, Smart SE, O'Neill F, MacCabe JH, et al
     Attrition in longitudinal studies among patients with schizophrenia and other psychoses; findings from the STRATA collaboration.
     Psychiatry Res. 2021;305:114211.
     PubMed     Abstract available
     
     
     
308. MISHRA A, Soni AB, Umate MS, Andrade C, et al
     An exploratory evaluation of predictors of duration of untreated psychosis in first-episode psychosis in lower income patients.
     Psychiatry Res. 2021;305:114203.
     PubMed     Abstract available
     
     
     
309. ZHU L, Zhang W, Zhu Y, Mu X, et al
     Cerebellar theta burst stimulation for the treatment of negative symptoms of schizophrenia: A multicenter, double-blind, randomized controlled trial.
     Psychiatry Res. 2021;305:114204.
     PubMed     Abstract available
     
     
     
310. SHOSHINA II, Hovis JK, Felisberti FM, Santos NA, et al
     Visual processing and BDNF levels in first-episode schizophrenia.
     Psychiatry Res. 2021;305:114200.
     PubMed     Abstract available
     
     
     
311. RABINOWITZ J, Rabinowitz AA
     Outlier-response pattern checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS).
     Psychiatry Res. 2021;303:114114.
     PubMed     Abstract available
     
     
     
312. VALERIO KE, Jonas KG, Perlman G, Bromet EJ, et al
     A comparison of cognitive performance in the Suffolk County cohort and their unaffected siblings.
     Psychiatry Res. 2021;303:114111.
     PubMed     Abstract available
     
     
     August 2021
313. KARTALCI S, Erbay MF, Kahraman A, Candir F, et al
     Evaluation of CSF flow dynamics in patients with schizophrenia using phase-contrast cine MRI.
     Psychiatry Res. 2021;304:114172.
     PubMed     Abstract available
     
     
     
314. REINFELD S, Caceda R, Gil R, Strom H, et al
     Can new onset psychosis occur after mRNA based COVID-19 vaccine administration? A case report.
     Psychiatry Res. 2021;304:114165.
     PubMed    
     
     
     
315. LYU J, Zhang J, Hennessy DA
     Characteristics and Risk Factors for Suicide in People with Schizophrenia in Comparison to Those without Schizophrenia.
     Psychiatry Res. 2021;304:114166.
     PubMed     Abstract available
     
     
     
316. YANG H, Xiao W, Yang M, Wang Y, et al
     Decreased neuregulin1beta1 in first episode and drug-naive patients with schizophrenia: Negative correlation with cognitive impairment.
     Psychiatry Res. 2021;304:114164.
     PubMed     Abstract available
     
     
     
317. SAHIN D, Hever F, Bossert M, Herwig K, et al
     Early and middle latency auditory event-related potentials do not explain differences in neuropsychological performance between schizophrenia spectrum patients and matched healthy controls.
     Psychiatry Res. 2021;304:114162.
     PubMed     Abstract available
     
     
     
318. DAURE C, Fortias M, Icick R, Delage C, et al
     Oral long acting antipsychotic penfluridol as a harm reduction treatment in a patient suffering from untreated schizophrenia and multiple drug dependence: A case report.
     Psychiatry Res. 2021;304:114147.
     PubMed     Abstract available
     
     
     
319. DEYO C, Langdon R
     Cognitive correlates of 'Formal Thought Disorder' in a non-clinical sample with elevated schizotypal traits.
     Psychiatry Res. 2021;302:113971.
     PubMed     Abstract available
     
     
     
320. BURNESS C, Corbet C, Beyene K, Webby C, et al
     Factors predicting high-dose and combined antipsychotic prescribing in New Zealand: High-dose antipsychotic prescribing.
     Psychiatry Res. 2021;302:113996.
     PubMed     Abstract available
     
     
     July 2021
321. DA MOTTA C, Pato MT, Barreto Carvalho C, Castilho P, et al
     The neurocognitive and functional profile of schizophrenia in a genetically homogenous European sample.
     Psychiatry Res. 2021;304:114140.
     PubMed     Abstract available
     
     
     
322. VOPPEL AE, de Boer JN, Brederoo SG, Schnack HG, et al
     Quantified language connectedness in schizophrenia-spectrum disorders.
     Psychiatry Res. 2021;304:114130.
     PubMed     Abstract available
     
     
     
323. BOSNJAK KUHARIC D, Makaric P, Kekin I, Rossini Gajsak L, et al
     Changes of neurocognitive status in patients with the first-episode psychosis after 18 months of treatment-A prospective cohort study.
     Psychiatry Res. 2021;304:114131.
     PubMed     Abstract available
     
     
     
324. GRACIA DFK, Gomes EMP, Coelho TA, Carriello M, et al
     Ficolin activation as a potential biomarker of the severity of schizophrenia.
     Psychiatry Res. 2021;304:114122.
     PubMed     Abstract available
     
     
     
325. KU BS, Pauselli L, Covington MA, Compton MT, et al
     Computational linguistic analysis applied to a semantic fluency task: A replication among first-episode psychosis patients with and without derailment and tangentiality.
     Psychiatry Res. 2021;304:114105.
     PubMed     Abstract available
     
     
     
326. SNELLEKSZ M, Dean B
     Lower levels of tubulin alpha 1b in the frontal pole in schizophrenia supports a role for changed cytoskeletal dynamics in the aetiology of the disorder.
     Psychiatry Res. 2021;303:114096.
     PubMed     Abstract available
     
     
     
327. VASKINN A, Engelstad KN, Torgalsboen AK, Rund BR, et al
     Childhood trauma, social cognition and schizophrenia: Specific association between physical neglect and cognitive theory of mind in homicide offenders.
     Psychiatry Res. 2021;303:114093.
     PubMed     Abstract available
     
     
     
328. JAGADHEESAN K, Danivas V, Itrat Q, Shekaran L, et al
     A 6-month study on the pattern of emergency department presentations for schizophrenia and other psychotic disorders during COVID-19 lockdown.
     Psychiatry Res. 2021;303:114081.
     PubMed     Abstract available
     
     
     June 2021
329. CORBERA S, Wexler BE, Bell MD, Pearlson G, et al
     Predictors of social functioning and quality of life in schizophrenia and autism spectrum disorder.
     Psychiatry Res. 2021;303:114087.
     PubMed     Abstract available
     
     
     
330. LI S, DeLisi LE, McDonough SI
     Rare germline variants in individuals diagnosed with schizophrenia within multiplex families.
     Psychiatry Res. 2021;303:114038.
     PubMed     Abstract available
     
     
     
331. CASADO-ORTEGA A, Vila-Badia R, Butjosa A, Del Cacho N, et al
     Social cognition and its relationship with sociodemographic, clinical, and psychosocial variables in first-episode psychosis.
     Psychiatry Res. 2021;302:114040.
     PubMed     Abstract available
     
     
     
332. ANDREOU D, Jorgensen KN, Wortinger LA, Engen K, et al
     Cytomegalovirus infection and IQ in patients with severe mental illness and healthy individuals.
     Psychiatry Res. 2021;300:113929.
     PubMed     Abstract available
     
     
     
333. BRAUN D, Schlossmann J, Haen E
     Asymmetric dimethylarginine in psychiatric disorders.
     Psychiatry Res. 2021;300:113901.
     PubMed     Abstract available
     
     
     May 2021
334. KELLY DL, Claxton A, Bidollari I, Du Y, et al
     Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil.
     Psychiatry Res. 2021;302:114030.
     PubMed     Abstract available
     
     
     
335. GUILLAUME F, Thomas E
     Recollection and familiarity in schizophrenia:An ERP investigation using face recognition exclusion tasks.
     Psychiatry Res. 2021;302:113973.
     PubMed     Abstract available
     
     
     
336. SCHEFFLER F, Phahladira L, Luckhoff H, du Plessis S, et al
     Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment.
     Psychiatry Res. 2021;302:114022.
     PubMed     Abstract available
     
     
     
337. MUNOZ-SAMONS D, Tor J, Rodriguez-Pascual M, Alvarez-Subiela X, et al
     Recent stressful life events and stress sensitivity in children and adolescents at clinical risk for psychosis.
     Psychiatry Res. 2021;303:114017.
     PubMed     Abstract available
     
     
     
338. HELLER C, Weiss T, Del Re EC, Swago S, et al
     Smaller subcortical volumes and enlarged lateral ventricles are associated with higher global functioning in young adults with 22q11.2 deletion syndrome with prodromal symptoms of schizophrenia.
     Psychiatry Res. 2021;301:113979.
     PubMed     Abstract available
     
     
     
339. ABEL DB, Salyers MP, Wu W, Monette MA, et al
     Quality versus quantity: Determining real-world social functioning deficits in schizophrenia.
     Psychiatry Res. 2021;301:113980.
     PubMed     Abstract available
     
     
     April 2021
340. ALBA L, Coll C, Saez S, Alonso L, et al
     New-onset psychosis: A case report of brief psychosis related to COVID-19 infection.
     Psychiatry Res. 2021;301:113975.
     PubMed    
     
     
     
341. UCOK A, Karakas B, Sahin OS
     Formal thought disorder in patients with first-episode schizophrenia: Results of a one-year follow-up study.
     Psychiatry Res. 2021;301:113972.
     PubMed     Abstract available
     
     
     
342. 
     Discrepancies between staff and gold standard ratings of schizophrenia symptom severity.
     Psychiatry Res. 2021;301:113963.
     PubMed    
     
     
     
343. DE PERI L, Deste G, Vita A
     Strucutural brain imaging at the onset of schizophrenia:What have we learned and what have we missed.
     Psychiatry Res. 2021;301:113962.
     PubMed     Abstract available
     
     
     
344. MEDALIA A, Saperstein AM, Stefancic A, Meyler S, et al
     Feasibility and acceptability of remotely accessed cognitive remediation for schizophrenia in public health settings.
     Psychiatry Res. 2021;301:113956.
     PubMed     Abstract available
     
     
     
345. XIE YJ, Xi YB, Cui LB, Guan MZ, et al
     Functional connectivity of cerebellar dentate nucleus and cognitive impairments in patients with drug-naive and first-episode schizophrenia.
     Psychiatry Res. 2021;300:113937.
     PubMed     Abstract available
     
     
     
346. PENNOU A, Lecomte T, Khazaal Y, Potvin S, et al
     Does theory of mind predict specific domains of social functioning in individuals following a first episode psychosis?
     Psychiatry Res. 2021;301:113933.
     PubMed     Abstract available
     
     
     
347. WANG YY, Hsu SH, Tsai HY, Cheng MC, et al
     Sequencing of the coding regions of GNBIL on chromosome 22q11.2 as a risk gene of schizophrenia.
     Psychiatry Res. 2021;300:113943.
     PubMed     Abstract available
     
     
     
348. SCHURHOFF F, Corfdir C, Pignon B, Lajnef M, et al
     No alteration of leukocyte telomere length in first episode psychosis.
     Psychiatry Res. 2021;301:113941.
     PubMed     Abstract available
     
     
     
349. VAERNES TG, Rossberg JI, Melle I, Nelson B, et al
     Basic self-disturbance in subjects at clinical high risk for psychosis: Relationship with clinical and functional outcomes at one year follow-up.
     Psychiatry Res. 2021;300:113942.
     PubMed     Abstract available
     
     
     
350. STRASSNIG MT, Miller ML, Moore R, Depp CA, et al
     Evidence for avolition in bipolar disorder? A 30-day ecological momentary assessment comparison of daily activities in bipolar disorder and schizophrenia.
     Psychiatry Res. 2021;300:113924.
     PubMed     Abstract available
     
     
     
351. SIDDIQUI SV, Nizamie SH, Siddiqui MA, Jahan M, et al
     Evaluation of N-400 Evoked Response Potential in schizophrenia: An endophenotype or a disease marker?
     Psychiatry Res. 2021;300:113907.
     PubMed     Abstract available
     
     
     March 2021
352. AU RWC, Sezto HNW, Lam VWM, Wan YT, et al
     Brief report: A randomized controlled trial of a compensatory cognitive training to improve prospective memory performance in people with schizophrenia or depression.
     Psychiatry Res. 2021;300:113914.
     PubMed     Abstract available
     
     
     
353. LI M, Liu Y, Qiu Y, Zhang J, et al
     The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
     Psychiatry Res. 2021;300:113899.
     PubMed     Abstract available
     
     
     
354. SIMON AE, Keller P, Cattapan K
     Commentary about social avoidance and its significance in adolescents and young adults.
     Psychiatry Res. 2021;297:113718.
     PubMed     Abstract available
     
     
     
355. TOYODA K, Hata T, Yamauchi S, Kinoshita S, et al
     A descriptive study of 10-year clozapine use from the nationwide database in Japan.
     Psychiatry Res. 2021;297:113764.
     PubMed     Abstract available
     
     
     
356. O'CONNOR C, Vaughan S
     Does selectively endorsing different approaches to treating mental illness affect lay beliefs about the cause and course of mental illness?
     Psychiatry Res. 2021;297:113726.
     PubMed     Abstract available
     
     
     February 2021
357. SREERAJ VS, Holla B, Ithal D, Nadella RK, et al
     Psychiatric symptoms and syndromes transcending diagnostic boundaries in Indian multiplex families: The cohort of ADBS study.
     Psychiatry Res. 2021;296:113647.
     PubMed     Abstract available
     
     
     
358. MORRIS E, Batallones R, Ryan J, Slomp C, et al
     Psychiatric genetic counseling for serious mental illness: Impact on psychopathology and psychotropic medication adherence.
     Psychiatry Res. 2021;296:113663.
     PubMed     Abstract available
     
     
     
359. CAMUS D, Dan Glauser ES, Gholamrezaee M, Gasser J, et al
     Factors associated with repetitive violent behavior of psychiatric inpatients.
     Psychiatry Res. 2021;296:113643.
     PubMed     Abstract available
     
     
     
360. GURCAN G, Senol SH, Yagcioglu AEA, Ertugrul A, et al
     Clinical risk factors, phenomenology and the impact of clozapine induced obsessive compulsive symptoms.
     Psychiatry Res. 2021;296:113665.
     PubMed     Abstract available
     
     
     
361. KHARE C, Mueser KT, Bahaley M, Vax S, et al
     Employment in people with severe mental illnesses receiving public sector psychiatric services in India.
     Psychiatry Res. 2021;296:113673.
     PubMed     Abstract available
     
     
     January 2021
362. KETHARANATHAN T, Pereira A, Reets U, Walker D, et al
     Brain changes in NF-kappaB1 and epidermal growth factor system markers at peri-pubescence in the spiny mouse following maternal immune activation.
     Psychiatry Res. 2021;295:113564.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.